Krystal J. Alligood

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Edgar R. Wood, Anne T. Truesdale, Octerloney B. McDonald et al. · Cancer Research · 2004 · 1.1K citations · Full text

Crystal Structure, Molecular Biology, Cell Growth +20

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

David W. Rusnak, Karen Lackey, Karen Affleck et al. · PubMed · 2001 · 737 citations

Pathology, Cell Proliferation, Cell Growth +16

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Wenle Xia, Robert J. Mullin, Barry R. Keith et al. · Oncogene · 2002 · 664 citations

Oncology, Medicine, Receptor Tyrosine Kinase +8

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

David W. Rusnak, Karen Affleck, Stuart Cockerill et al. · PubMed · 2001 · 297 citations

Potential Therapy, Tumor Biology, Oncology +18

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb^®, GW572016) in an expanded panel of human normal and tumour cell lines

David W. Rusnak, Krystal J. Alligood, Robert J. Mullin et al. · Cell Proliferation · 2007 · 174 citations · Full text